CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. The rise in research activities and availability of funding for R&D
4.1.2. Development of advanced technological peptide synthesisers
4.1.3. Increasing use of peptides in pharmaceutical drugs
4.2. Market Restraints & Challenges
4.2.1. Lack of a unified set of regulations for therapeutic peptides
4.2.2. Issues and problems associated with the route of administration of peptide drugs
4.3. Market Opportunities
4.3.1. Emerging markets in the APAC region
CHAPTER 5. GLOBAL PEPTIDE SYNTHESIS MARKET – BY PRODUCT
5.1. Equipment
5.1.1. Peptide Synthesizers
5.1.2. Lyophilizers
5.1.3. Chromatography Equipment
5.2. Reagents
CHAPTER 6. GLOBAL PEPTIDE SYNTHESIS MARKET – BY TECHNOLOGY
6.1. Solid Phase Peptide Synthesis
6.2. Solution Phase Synthesis
6.3. Hybrid and Recombinant Technology
CHAPTER 7. GLOBAL PEPTIDE SYNTHESIS MARKET – BY END USER
7.1. Academic & Research Institutes
7.2. Pharmaceutical & Biotechnology Companies
7.3. CROs and CMOs
CHAPTER 8. GLOBAL PEPTIDE SYNTHESIS MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL PEPTIDE SYNTHESIS MARKET - COMPANY PROFILES
9.1. Bachem
9.2. PolyPeptide Group
9.3. Thermo Fisher Scientific Inc.
9.4. Biomatik Corporation
9.5. Proimmune Ltd
9.6. LifeTein LLC
9.7. CPC Scientific
9.8. New England Peptide Inc.
9.9. AnaSpec
9.10. GenScript
9.11. ScinoPharm
9.12. Guizhou Xinbang Pharmaceutical Co., Ltd
9.13. USVPeptides
9.14. Hybio Pharmaceutical Co., Ltd
9.15. GL Biochem Ltd
CHAPTER 10. GLOBAL PEPTIDE SYNTHESIS MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
